Oral Selexipag versus Inhaled Treprostinil Effect on Pulmonary Arterial Hypertension

被引：0
|
作者：
Nguyen, J. Q. [1 ]
Teklu, Y. [2 ]
Wu, S. [2 ]
Kolaitis, N. A. [1 ]
De Marco, T. [1 ]
Fanous, S. M. [1 ]
机构：
[1] Univ Calif San Francisco, San Francisco, CA 94143 USA
[2] Univ Calif San Diego, San Diego, CA 92103 USA
来源：
JOURNAL OF HEART AND LUNG TRANSPLANTATION | 2022年 / 41卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1056
引用
收藏
页码：S427 / S427
页数：1
相关论文
共 50 条
  • [1] Functional Outcomes Of Selexipag Versus Inhaled Treprostinil For The Treatment Of Pulmonary Arterial Hypertension
    Pallazola, V. A.
    Visovatti, S.
    McLaughlin, V.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [2] Transition From Inhaled Treprostinil to Selexipag in Pulmonary Arterial Hypertension
    El-Kersh, Karim
    Smith, J. Shaun
    [J]. AMERICAN JOURNAL OF THERAPEUTICS, 2017, 24 (05) : E620 - E621
  • [3] Comparative evaluation of costs and healthcare resource utilization of oral selexipag versus inhaled treprostinil or oral treprostinil in patients with pulmonary arterial hypertension
    Papademetriou, Eros
    Liu, Xing
    Beaudet, Amelie
    Tsang, Yuen
    Potluri, Ravi
    Panjabi, Sumeet
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2023, 26 (01) : 644 - 655
  • [4] Assessment of Inhaled Treprostinil Palmitil, Inhaled and Intravenous Treprostinil, and Oral Selexipag in a Sugen/Hypoxia Rat Model of Pulmonary Arterial Hypertension
    Corboz, Michel R.
    Plaunt, Adam J.
    Malinin, Vladimir S.
    Li, Zhili
    Gauani, Helena
    Chun, Donald
    Cipolla, David
    Perkins, Walter R.
    Chapman, Richard W.
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2022, 383 (01): : 103 - 116
  • [5] TRANSITION OF IV TREPROSTINIL TO ORAL SELEXIPAG IN PULMONARY ARTERIAL HYPERTENSION
    Mahoney, Roshan
    Sweidan, Alexander
    Yaghmour, Bassam
    [J]. CHEST, 2021, 160 (04) : 2229A - 2229A
  • [6] TRANSITION FROM SELEXIPAG TO ORAL TREPROSTINIL IN A PATIENT WITH PULMONARY ARTERIAL HYPERTENSION
    Patel, Amol
    Safdar, Zeenat
    [J]. CHEST, 2018, 154 (04) : 1023A - 1024A
  • [7] Transition from selexipag to oral treprostinil in a patient with pulmonary arterial hypertension
    Oriaku, Ifeoma
    Patel, Amol
    Safdar, Zeenat
    [J]. PULMONARY CIRCULATION, 2020, 10 (01)
  • [8] Transition From Oral Treprostinil to Selexipag in a Patient With Pulmonary Arterial Hypertension
    Verlinden, Nathan J.
    Walter, Claire
    Kanwar, Manreet
    Raina, Amresh
    [J]. ANNALS OF PHARMACOTHERAPY, 2019, 53 (07) : 764 - 765
  • [9] Beneficial Effects of Treprostinil Palmitil in a Sugen/Hypoxia Rat Model of Pulmonary Arterial Hypertension; a Comparison with Inhaled and Intravenous Treprostinil and Oral Selexipag
    Corboz, M. R.
    Plaunt, A. J.
    Malinin, V.
    Li, Z.
    Gauani, H.
    Chun, D.
    Cipolla, D.
    Perkins, W.
    Chapman, R. W.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
  • [10] Inhaled treprostinil and pulmonary arterial hypertension
    Nadler, Samuel T.
    Edelman, Jeffrey D.
    [J]. VASCULAR HEALTH AND RISK MANAGEMENT, 2010, 6 : 1115 - 1124
12345